Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
The ruling brings closure to a nearly decade-long investigation into hospital operations and healthcare delivery practices
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
Minister J.P. Nadda holds bilateral meeting with Helen Clark, Board Chair of the Partnership for Maternal, Newborn and Child Health in Geneva
The competition received over 42 entries from nursing colleges across Maharashtra
Growth was driven by expansion across key business segments, improving efficiencies, and sustained demand across institutional and retail channels
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management
Net income more than doubled to 2.763 billion euros, while core earnings per share climbed 12.9 percent to 2.71 euros
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Subscribe To Our Newsletter & Stay Updated
